Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel R Denmeade

Showing results (81-90 of 155) with videos related to

Pageof 16
Sort By:
Molecular Cancer Therapeutics|November 16, 2004
Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancerSamuel Janssen, Carsten M Jakobsen, D Marc Rosen, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 30, 2020
The association of sex steroid hormone concentrations with non-alcoholic fatty liver disease and liver enzymes in US menHong Phan, Aline Richard, Mariana Lazo, et al.
The Prostate|January 27, 2004
Anti-tumor effect of combination therapy with intratumoral controlled-release paclitaxel (PACLIMER microspheres) and radiationRena G Lapidus, Wenbin Dang, David Marc Rosen, et al.
BJU International|March 25, 2021
Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancerCatherine H Marshall, Jessa Tunacao, Varun Danda, et al.
The Prostate|November 23, 2005
Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrugSamuel Janssen, D Marc Rosen, Rebecca M Ricklis, et al.
Journal of the National Cancer Institute|July 3, 2003
Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancerSamuel R Denmeade, Carsten M Jakobsen, Samuel Janssen, et al.
The Prostate|January 23, 2003
Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer modelsSamuel R Denmeade, Lori J Sokoll, Susan Dalrymple, et al.
Bioorganic & Medicinal Chemistry|January 18, 2006
Natural products as starting materials for development of second-generation SERCA inhibitors targeted towards prostate cancer cellsHelmer Søhoel, Anne-Marie Lund Jensen, Jesper V Møller, et al.
The Oncologist|February 12, 2020
A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell CarcinomaAndrew W Hahn, Charles Drake, Samuel R Denmeade, et al.
Plos One|September 6, 2007
The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherinSushant K Kachhap, Dennis Faith, David Z Qian, et al.
Pageof 16

Showing results (81-90 of 155) with videos related to

Sort By:
Pageof 16
Molecular Cancer Therapeutics|November 16, 2004
Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancerSamuel Janssen, Carsten M Jakobsen, D Marc Rosen, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 30, 2020
The association of sex steroid hormone concentrations with non-alcoholic fatty liver disease and liver enzymes in US menHong Phan, Aline Richard, Mariana Lazo, et al.
The Prostate|January 27, 2004
Anti-tumor effect of combination therapy with intratumoral controlled-release paclitaxel (PACLIMER microspheres) and radiationRena G Lapidus, Wenbin Dang, David Marc Rosen, et al.
BJU International|March 25, 2021
Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancerCatherine H Marshall, Jessa Tunacao, Varun Danda, et al.
The Prostate|November 23, 2005
Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrugSamuel Janssen, D Marc Rosen, Rebecca M Ricklis, et al.
Journal of the National Cancer Institute|July 3, 2003
Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancerSamuel R Denmeade, Carsten M Jakobsen, Samuel Janssen, et al.
The Prostate|January 23, 2003
Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer modelsSamuel R Denmeade, Lori J Sokoll, Susan Dalrymple, et al.
Bioorganic & Medicinal Chemistry|January 18, 2006
Natural products as starting materials for development of second-generation SERCA inhibitors targeted towards prostate cancer cellsHelmer Søhoel, Anne-Marie Lund Jensen, Jesper V Møller, et al.
The Oncologist|February 12, 2020
A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell CarcinomaAndrew W Hahn, Charles Drake, Samuel R Denmeade, et al.
Plos One|September 6, 2007
The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherinSushant K Kachhap, Dennis Faith, David Z Qian, et al.
Pageof 16